ViiV files two-drug HIV maintenance regimen

to bring the new combination to market ahead of a new triplet regimen from Gilead Sciences, its fiercest competitor in the HIV category. ... Gilead has just reported the results of four phase III trials of its three-drug combo of new integrase inhibitor

Finalists 2017

for Novartis Pharma AG. Going Beyond Undetectable. by dna Communications. for Gilead.

Gilead plans fightback against HIV arch-rival ViiV

Gilead plans fightback against HIV arch-rival ViiV. Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq. ... Gilead has reported the results of four phase III trials of a new HIV combination therapy pairing its Descovy

Bayer's lymphoma drug copanlisib gets speedy FDA review

Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... First launched in 2014, Zydelig brought in $168m for Gilead over

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 5)